Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Coronavirus: Novavax gets $1.6 billion in federal funding

<< Previous

Bullboard Posts

Next >>

Comment by 90guppyon Jan 13, 2021 9:39am

115 Views

Post# 32283781

RE:RE:RE:Coronavirus: Novavax gets $1.6 billion in federal funding

be patient and wait for the results of the ongoing test, companies like Novavax and Inovio had been working wth USAMRIID for years and years long before covid and they had established relationship with USAMRIID, be patient and be thankful VXL was able to collaborate with USAMRIID

bligicka wrote: So where's Vaxil's funding ....why are they doing pp's when other unproven vaccine makers are getting billions .....Vaxil has been working on this virus for almost a full year and still don't even have phase timelines .......

90guppy wrote:
thats what you get when you work with USAMRIID, you get your foot in the funding door.

bligicka wrote: